Recombinant SARS-Cov-2 Spike protein RBD (BA.2.86), (HEK293), APC Conjugated
Applications
Reactivity
| Overview | |
| Catalog # | bs-43195P-APC-100ug |
| Product Name | Recombinant SARS-Cov-2 Spike protein RBD (BA.2.86), (HEK293), APC Conjugated |
| Applications |
OTHERS
|
| Reactivity | Others |
| Specifications | |
| Conjugation | APC |
| Source | Recombinant SARS-Cov-2 Spike protein RBD (BA.2.86) is expressed in HEK293 cell with C-His. It contains the amino acid sequence of 319-537/1273 |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Target | |
| Swiss Prot | P0DTC2 |
| Background | The SARS-CoV-2 spike (S) protein is the target of vaccine design efforts to end the COVID-19 pandemic. Despite a low mutation rate, isolates with the D614G substitution in the S protein appeared early during the pandemic, and are now the dominant form worldwide. Here, we analyze the D614G mutation in the context of a soluble S ectodomain construct. |